Noile-Immune Biotech
Basic Information
- Stock Code
- 4893
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Tokyo
- Establishment Year
- April 2015
- Listing Year
- June 2023
- Official Website
- https://www.noile-immune.com/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- GNI Group, Heartseed, Nexela Pharma, PeptiDream, SanBio, Helios, Fanpep, Rena Science, QualiPs, Takara Bio, Second X, Leon, Japan Tissue Engineering
Overview
Noile-Immune Biotech is a bio-venture established in 2015 that focuses on developing cancer immunotherapy, featuring cutting-edge technology originating from the National Cancer Center Research Institute and Yamaguchi University.
Current Situation
Noile-Immune Biotech, which listed in June 2023, is advancing research and development of cell therapies for solid tumors using the latest immunotherapy technologies. It closely collaborates with the National Cancer Center Research Institute and competes with domestic and international rivals in the CAR-T therapy field. In 2023, it raised funds to initiate clinical trials, accelerating its entry into the cancer immunotherapy market. Moving forward, it aims to commercialize pharmaceuticals, expand scale, and plan clinical applications primarily in Japanese medical institutions. Environmentally, it emphasizes sustainable medical innovation centered on biotech and continues developing advanced, specialized technologies in the pharmaceutical sector. As a promising growth area, it focuses on pioneering new immune mechanisms for cancer treatment, promoting revenue base strengthening and global expansion in the mid-to-long term. Currently, it is expanding R&D expenses and strengthening industry-academia collaboration, with multifaceted business development in view for the future.
Trivia
Interesting Facts
- Technology seed company from the National Cancer Center Research Institute and Yamaguchi University
- Listed on TSE Growth just 8 years after founding
- Domestic first challenge in applying CAR-T therapy to solid tumors
- Develops a wide range of immune-related reagents across multiple fields
- Emphasizes industry-academia collaboration and maintains advanced research environment
- Bio venture with rapidly increasing patent applications
- Highly evaluated in international academic presentations
- Capable of rapid response to clinical applications of cutting-edge technologies
- Developed proprietary platform using CAR-T technology
- Received multiple awards for immune-related products
- Multiple pharmaceutical candidates entering clinical development phase
- Multiple PhD-holding researchers on staff
- Laboratory and head office located in central Tokyo
- Customization capabilities for patient-specific treatments as a strength
- Possesses cutting-edge equipment for treatment efficacy verification
Hidden Connections
- Holds numerous co-owned patents with the National Cancer Center Research Institute
- Participates as a key member in international CAR-T collaboration conferences
- Contributes to regional economic support as a Yamaguchi University-spun bio venture
- Several joint research projects underway with rival companies
- Cooperates in training for medical institutions and focuses on human resource development
- Conducts numerous technology presentations at domestic and international bio conferences
- Advances R&D aligned with government bio industry policies
- Exploring partnerships with multiple pharmaceutical companies
Future Outlook
Growth Drivers
- Rapid growth in the solid tumor immunotherapy market
- Increasing demand for cancer treatment due to aging society
- Technological innovation through strengthened collaboration with national research institutions
- Expansion of new indications for CAR-T technology
- Acceleration of clinical trials due to domestic and international regulatory easing
- Expansion of bio drug discovery support market
- Diversification and commercialization of immune-related products
- Improved development efficiency through artificial intelligence
- Aggressive expansion into international markets
- Spread of personalized medicine in medical settings
- Increase in external funding for research expenses
- Expansion of applications in regenerative medicine field
Strategic Goals
- Completion of commercialization for solid tumor immune cell therapy
- Achievement of standard treatment status in major domestic medical institutions
- Expansion of technology licensing to overseas markets
- Diversification of bio-related product lineup
- Achievement of consolidated sales exceeding ¥10 billion
- Technological breakthrough in new immunotherapy development
- Strengthening of R&D and manufacturing systems
- Establishment of sustainable pharmaceutical processes
- Provision of innovative treatments tailored to market needs
- Expansion of social contribution activities and improved transparency
Business Segments
Cell Therapy Business for Medical Institutions
- Overview
- Provides cutting-edge cancer immune cell therapy products to medical institutions.
- Competitiveness
- Joint development capabilities with the National Cancer Center Research Institute
- Customers
-
- University Hospitals
- Cancer Specialty Hospitals
- Immunotherapy Clinics
- Regenerative Medicine Facilities
- Research Hospitals
- Products
-
- CAR-T Therapy Cell Preparations
- Immune Activation Factors
- Clinical Trial Therapeutic Cells
- Patient-Specific Custom Treatment Kits
- Treatment Efficacy Monitoring Technology
Research Support Services for Pharmaceutical Companies
- Overview
- Provides a variety of reagents and services for drug discovery and pharmaceutical development.
- Competitiveness
- Versatility in applying the latest gene and immune technologies
- Customers
-
- Major Pharmaceutical Companies
- Bio Ventures
- Drug Discovery Research Institutions
- CDMO Companies
- Bioinformatics Companies
- Products
-
- Immune System Bio Reagents
- Gene Editing Reagents
- Antibody Development Support Kits
- Data Analysis Services
- Cell Models for Drug Efficacy Verification
Reagent Sales for Bio Research Institutions
- Overview
- Supplies a wide range of bio reagents supporting basic research.
- Competitiveness
- High-quality and customizable product lineup
- Customers
-
- Universities and Public Research Institutions
- Private Research Institutions
- Pharmaceutical Research Labs
- Contract Research Organizations
- Medical Technology Corporations
- Products
-
- Immune Analysis Antibodies
- Cell Culture Reagents
- Protein Purification Kits
- Gene Expression Analysis Kits
- Cell Function Evaluation Reagents
Clinical Research Support Services
- Overview
- Conducts cell analysis and biomarker evaluation services for clinical trials.
- Competitiveness
- Specialized clinical research expertise and equipment collaboration
- Customers
-
- University Hospital Clinical Research Departments
- Medical Device Manufacturers
- Clinical Trial Support Companies
- Pharmaceutical Development Institutions
- Public Research Grant Organizations
- Products
-
- Clinical Cell Analysis Services
- Biomarker Development Support
- Clinical Trial Reagents
- Clinical Data Statistical Analysis
- Patient Sample Bank
Technology Licensing and Joint Research
- Overview
- Promotes licensing of immune and cell therapy technologies as well as joint research.
- Competitiveness
- National Cancer Center Research Institute-endorsed technology
- Customers
-
- Domestic Pharmaceutical Companies
- Overseas Bio Ventures
- University Labs
- Medical Device Companies
- Regional Base Companies
- Products
-
- Immunotherapy Technology Licensing
- Cell Culture Technology Sharing
- Joint Drug Discovery Development
- Technology Evaluation Analysis
- Scout Joint Research
Education and Training Program Provision
- Overview
- Training business aimed at disseminating immunotherapy technologies and developing human resources.
- Competitiveness
- Advanced education programs by specialist physicians and researchers
- Customers
-
- Medical Professionals
- Researchers
- Pharmaceutical Company Training Teams
- Graduate Students
- Bio Technicians
- Products
-
- Immunotherapy Basics Course
- Research Technology Training
- Clinical Treatment Operation Education
- Product Usage Seminars
- Seminars and Workshops
Competitive Advantage
Strengths
- Strong collaboration with the National Cancer Center Research Institute
- Possession of advanced CAR-T cell technology
- Development of solid tumor-specific immunotherapy
- High research foundation as a university-spun bio venture
- Development capabilities for diverse bio reagents and cell products
- High technological innovation and applicability
- Team of experienced scientists
- Rapid clinical development system
- Collaboration with major domestic medical institutions
- Specialized knowledge in bio drug discovery
- Strategy envisioning global expansion
- Partnership building with pharmaceutical companies
- Broad BtoB and medical field product portfolio
- Active investment in R&D expenses
- Meticulous clinical trial programs
Competitive Advantages
- Proprietary CAR-T products based on National Cancer Center Research Institute technology
- High-precision immunotherapy technology targeting solid tumors
- Integrated development fusing gene editing and immunotherapy
- Vertically integrated system from specialized reagents to therapeutic products
- Early technology commercialization through joint development with research institutions
- Proprietary cell culture and activation technologies
- Market needs response via diverse product lineup
- Utilization of medical institution networks in the domestic market
- Expansion potential in precision medicine field
- Customizable product design
- Faster development compared to overseas bio ventures
- Enhanced capabilities for patient-specific treatments
- Research on technologies to reduce immunotherapy side effects
- Reliability backed by continuous technological innovation
- Uniqueness of treatment efficacy monitoring technology
Threats
- Intensifying technological competition with major pharmaceutical companies
- Uncertainty and delay risks in clinical trial results
- Impact of regulatory approval delays and strengthened legal regulations
- Funding shortage risks due to high R&D costs
- Speed of technological innovation by competing bio ventures
- Patent infringement risks in emerging markets
- Intensifying price competition in the immunotherapy market
- Resistance to adoption of new treatments in medical settings
- Material supply instability due to international situations
- Intensifying competition for highly skilled talent
- Challenges accompanying scale-up of manufacturing processes
- Need to rethink business strategy due to changes in market needs
Innovations
2023: Initiation of Clinical Trials for CAR-T Therapy Targeting Solid Tumors
- Overview
- Initiated clinical trials for CAR-T therapy targeting solid tumors through joint research with the National Cancer Center Research Institute.
- Impact
- Contributes to improved treatment efficacy and new market development
2024: Completion of Development for Immune Activation Cytokine Preparation
- Overview
- Completed research on cytokine preparations that enhance immune response, advancing to product preparation stage.
- Impact
- Diversifies treatment efficacy and promotes combination therapies
2022: Practical Implementation of High-Sensitivity Biomarker Detection Technology
- Overview
- Practicalized high-sensitivity biomarker detection technology for cancer diagnosis and treatment monitoring.
- Impact
- Enhances early diagnosis possibilities and optimizes treatment
2023: Expansion of Gene Editing Reagent Lineup for Drug Discovery Support
- Overview
- Expanded product line of gene editing reagents applying CRISPR-Cas9 technology.
- Impact
- Improves efficiency and speed of drug discovery research
2024: Introduction of Automation Technology for Clinical Cell Culture Systems
- Overview
- Introduced automation and standardization technology for cell culture, significantly improving production efficiency.
- Impact
- Reduces production costs and stabilizes quality
Sustainability
- Development of technologies to reduce environmental impact of bioprocesses
- Optimization of manufacturing efficiency to reduce waste
- Dissemination of advanced medical technologies as social responsibility
- Compliance with ethical guidelines in research activities
- Promotion of diverse talent utilization and comfortable workplace environment
- Social contribution activities through collaboration with regional healthcare
- Improvement of energy usage efficiency and energy-saving initiatives
- Sustainable supply chain management
- Advancement of research on recyclable bio-materials
- Promotion of health management and enriched employee welfare